B-cell Acute Lymphoblastic Leukemia Clinical Trials

62 recruitingLast updated: June 18, 2026

There are 62 actively recruiting b-cell acute lymphoblastic leukemia clinical trials across 29 countries. Studies span Phase 1, Phase 2, Phase 3, Early Phase 1, Not Applicable. Top locations include Houston, Texas, United States, Philadelphia, Pennsylvania, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


B-cell Acute Lymphoblastic Leukemia Trials at a Glance

62 actively recruiting trials for b-cell acute lymphoblastic leukemia are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 1 with 31 trials, with the heaviest enrollment activity in Houston, Philadelphia, and Beijing. Lead sponsors running b-cell acute lymphoblastic leukemia studies include The First Affiliated Hospital of Soochow University, Beijing GoBroad Hospital, and Institute of Hematology & Blood Diseases Hospital, China.

Browse b-cell acute lymphoblastic leukemia trials by phase

Treatments under study

About B-cell Acute Lymphoblastic Leukemia Clinical Trials

Looking for clinical trials for B-cell Acute Lymphoblastic Leukemia? There are currently 41 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Acute Lymphoblastic Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Acute Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 1Phase 2

Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

B-cell Acute Lymphoblastic Leukemia
Liping Dou20 enrolled1 locationNCT07575919
Recruiting
Phase 3

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center130 enrolled5 locationsNCT07223021
Recruiting
Phase 3

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 1Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled70 locationsNCT06395103
Recruiting
Phase 2Phase 3

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC340 enrolled3 locationsNCT07570173
Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca236 enrolled80 locationsNCT06137118
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 1Phase 2

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD115 enrolled1 locationNCT05480449
Recruiting
Phase 1

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Kansas Medical Center54 enrolled1 locationNCT06879340
Recruiting
Phase 1Phase 2

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
Liping Dou30 enrolled1 locationNCT07575971
Recruiting

Long-term Follow up Local Registry Study of Kymriah in South Korea

B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals500 enrolled16 locationsNCT06785818
Recruiting
Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center60 enrolled1 locationNCT07153796
Recruiting

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

B-cell Acute Lymphoblastic Leukemia (B-ALL)
St. Jude Children's Research Hospital80 enrolled1 locationNCT07048535
Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Phase 1Phase 2

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1Phase 2

Co-administration of CART22-65s and huCART19 for B-ALL

B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD93 enrolled1 locationNCT05674175
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579